Industry Thought Leaders Edit Two Reference Books Essential for Advancing Regenerative Medicine

CARLSBAD, Calif.–Invitrogen, a division of Life Technologies Corporation (NASDAQ:LIFE), today announced that four of its scientists whose work is focused in stem cell research are editors of two recently published books that capture many of the latest findings in this field and provide comprehensive guidelines for applying technologies to advance related applications. Emerging Technology Platforms for Stem Cells, by John Wiley & Sons, and Regulatory Networks in Stem Cells, by Springer Science + Business Media are expected to be essential references for researchers, scientists and clinicians applying stem cell science to personalized and regenerative medicine.

Emerging Technology Platforms for Stem Cells was edited by Uma Lakshmipathy, Ph.D., a principal scientist, and lead editor of the book; Jon Chesnut, a research and development director; and Bhaskar Thyagarajan, Ph.D., a program manager, all from Life Technologies. This book presents general principles and methodologies for professionals involved in stem cell research. It focuses on current technologies that can help scientists to overcome some of the challenges they face in developing stem cells as therapeutic agents, incorporating scientific papers by 78 authors from 10 countries.

Regulatory Networks in Stem Cells was edited by Mohan Vemuri, Ph.D., a research and development director at Life Technologies; and by Vinagolu K. Rajasekhar, Ph.D., a senior research scientist, at Memorial Sloane-Kettering Cancer Center in New York. This book describes key factors involved in stem cell pluripotency, maintenance, and directed differentiation towards specific lineages, and how regulation of these complex events results in stem cell fate choices in normal and disease conditions. The book includes writings of 200 authors from around the world.

Uma Lakshmipathy, Ph.D., Principal Scientist, Invitrogen Primary and Stem Cell Systems at Life Technologies

“We think about how technology addresses challenges related to stem cell research daily, and we realized that there are no resources out there – nothing on the market – that describes these emerging technologies and how they will apply to therapy and drug discovery. We wanted a book that would be a window to the future.”

Mohan Vemuri, Ph.D., Research and Development Director, Invitrogen Primary and Stem Cell Systems at Life Technologies

“Regulatory networks are the molecular systems operating at the DNA, RNA and protein levels that play a crucial role in making the stem cells do what they’re supposed to do in normal development, or in cellular repair in disease.”

Additional Resources

Emerging Technology Platforms for Stem Cells – Overview, reviews, and order information

Regulatory Networks in Stem Cells – Overview, reviews, and order information

Invitrogen Stem Cell Solutions

Invitrogen Leadership in Regenerative Medicine

Invitrogen is a leading provider of platform independent, essential life science technologies for disease and drug research, bioproduction and diagnostics. It is the premier provider of products and services for advancing the field of regenerative medicine. Invitrogen’s efforts are focused on supplying researchers and developers with the most comprehensive suite of products for advancing cell therapy efforts, including the industry’s premier portfolio of tools and reagents for stem cell research. It also focuses on creating unique primary and stem cell models for better and more efficient drug screening. Invitrogen, together with Applied Biosystems ¯ a global leader in providing innovative instrument systems to accelerate academic and clinical research, drug discovery and development, pathogen detection and forensic DNA analysis ¯ is part of Life Technologies Corporation, which markets the life science industry’s most comprehensive portfolio of solutions for molecular and cell biology. Invitrogen and Applied Biosystems products are used in nearly every major laboratory in the world.

For more information, please visit: www.invitrogen.com and www.appliedbiosystems.com.

About Life Technologies

Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: www.lifetechnologies.com.

Life Technologies’ Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

Copyright 2009. Life Technologies Corporation. All rights reserved. Invitrogen is a trademark of Life Technologies in the US and/or certain other countries.